drugset / Trial / NCT03774173
Comparison of Aramchol Concentrations With Once or Twice Daily Dosing
Phase 1
Completed
16 enrolled
Galmed Pharmaceuticals Ltd
Analyst Research Laboratories · collabDiamond Pharma Services Regulatory Affairs Consultancy · collabHammersmith Medicines Research · collab
RandomizedCrossoverOpen-labelOther
Summary
The trial is an open-label, 2-period, randomised, crossover study of the plasma concentrations of aramchol, in which subjects will receive oral doses of aramchol at 300 mg twice daily and 600 mg once daily.
Timeline
- Start
- 2018-12-08
- Primary completion
- 2019-02-03
- Completion
- 2019-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aramchol | Other / unclassified | 300 mg | Oral |
| Subject | Aramchol | Other / unclassified | 600 mg | Oral |
Indications
No indication recorded.